Kairos Pharma, Ltd.'s latest marketcap:
As of 07/29/2025, Kairos Pharma, Ltd.'s market capitalization has reached $9.69 M. According to our data, Kairos Pharma, Ltd. is the 40863th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 9.69 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -3,542,000 |
| Shares Out | 16.85 M |
| EPS (ttm) | -0.28 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/23/2025 |
Kairos Pharma, Ltd.'s yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/29/2025 | $9.69 M | -19.75% | 40863 |
| 12/31/2024 | $19.53 M | n/a |
Company Profile
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.
Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer.
It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA.
The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016.
Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Frequently Asked Questions
-
What is Kairos Pharma, Ltd.'s (KAPA) current market cap?As of 07/29/2025, Kairos Pharma, Ltd. (including the parent company, if applicable) has an estimated market capitalization of $9.69 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Kairos Pharma, Ltd. (KAPA) rank globally by market cap?Kairos Pharma, Ltd. global market capitalization ranking is approximately 40863 as of 07/29/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.